Disturbing new evidence emerges in high-profile Erin Patterson case, as her estranged husband Simon suspected she had tried to poison him multiple times.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.
Disturbing new evidence emerges in high-profile Erin Patterson case, as her estranged husband Simon suspected she had tried to poison him multiple times.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Expedia Group reports strong Q2 2025 results, raises full-year guidance amid international gains, sending shares higher.